NanoViricides, Inc. (NNVC)
NYSEAMERICAN: NNVC · Real-Time Price · USD
0.960
+0.033 (3.61%)
Mar 6, 2026, 4:00 PM EST - Market closed
NanoViricides Employees
NanoViricides had 7 employees as of June 30, 2025. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,188,349
Market Cap
20.72M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Citius Pharmaceuticals | 23 |
| Daré Bioscience | 23 |
| VYNE Therapeutics | 13 |
| Genenta Science | 13 |
| Intensity Therapeutics | 7 |
| Lexaria Bioscience | 7 |
| Marker Therapeutics | 5 |
| Cadrenal Therapeutics | 4 |
NNVC News
- 23 days ago - MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides - Accesswire
- 25 days ago - Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides - Accesswire
- 4 weeks ago - NanoViricides President Dr. Diwan Interviewed by Mission Matters' Adam Torres - Accesswire
- 7 weeks ago - NanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza Wave - NV-387 is Effective Against H3N2 - Accesswire
- 3 months ago - NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles - Accesswire
- 3 months ago - NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position - Accesswire
- 4 months ago - NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2 - Accesswire
- 4 months ago - NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close - Accesswire